It might take longer to see, but it is there. And then you have initiatives like Mia, which, really speak to new consumers. And when we think about what we’ve been doing over the last couple of days here in Japan, the excitement level from the potential launch of Mia is high and the local partners and clinics understand very well that this can be a major game changer in breast aesthetics in Japan.
Juan Jose Chacon-Quiros : And Matt, I would just offer too that, we are poised into the two largest markets in the world, in the United States and China, so that capacity is needed for those initiatives along with the continued share gains we’re doing in other markets around the world.
Unidentified Analyst : Right. Thanks, Raj. Thanks, J.J.
Operator: Our next question comes on the line of Neil Chatterji with B. Riley. Please proceed with your question.
Neil Chatterji: Yes. Thanks for taking the questions. So maybe just on Mia Femtech I guess for the countries where you’ve already started to receive the regulatory clearances, I believe it might have been Latin America and Asia. Just curious if you could talk about the early experiences you are seeing there in those regions? And then also perhaps if you have an update on the potential launch in Japan and your clinic partner strategy there.
Raj Denhoy: Yes, to be clear, we have not launched in any country. We have been doing early experience cases Latin America and in Japan. And our plan is to continue to use those insights from patients that have undergone the procedure as part of our work towards the launch. I’ll give you an example. We had an engineer who had the procedure on Tuesday, as you saw in the Mia Investor Day and got married on a Saturday. And her testimonial is so strong because basically no stigma of any type around the procedure and her enjoying a big day in the most profound way. So, this is like what we are about. We are working towards expanding markets and we just have to be patient for the launch. But when it happens, I think, you’ll notice that this is a true new option. The consumer insights that we are gathering are strong and we continue to have both qualitative and quantitative analysis that we will share in due time.
Neil Chatterji: Got it. And maybe just one quick follow-up, just in terms of the kind of the ASP strategy, I think, in the slides from the Mia Day, it kind of gave a range of like 2,500 to, to 3,500. So just kind of curious around the assumptions around that if that’s kind of related to the regional nuances or what that’s based on?
Raj Denhoy: Well, it’s based on willingness to pay analysis and this is conducted market-to-market. We don’t want to under-price or price out consumers. So that’s the work around that. Of course, we’re always going to try to do as best as possible, but that’s why we are always conservative on our pricing when it’s given in this fashion.
Juan Jose Chacon-Quiros: And I think Neil, you probably appreciate too in the slides that we presented and talked about at that day, that if you look at the economics to the surgeon at those price points, given the speed at which they can do the procedure, the efficiency at which they can run their practice if they have devoted time to Mia, even at those price points, it still represents quite a bit of value to the surgeon. And so I think it’s a question of finding that sweet spot that creates value for us as a company, but also for our partners and surgeons and absolutely for the women who received the procedure.
